5-ALA fluorescence-assisted surgery in pediatric brain tumors: Report of three cases and review of the literature

British Journal of Neurosurgery

Volumn 28, Issue 6, 2014, Pages 750-754

  Barbagallo, Giuseppe M V ^a   Certo, Francesco ^a   Heiss, Kathrin ^a   Albanese, Vincenzo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

5 Aminolevulinic acid; Children; Fluorescence; Glioma; Medulloblastoma; Off label drug; Paediatric; Safety

Indexed keywords

AMINOLEVULINIC ACID; GADOLINIUM; PHOTOSENSITIZING AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURGERY; CASE REPORT; CHILD; CHILDHOOD CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOREDUCTIVE SURGERY; DRUG INDICATION; FEMALE; FLUORESCENCE; FLUORESCENCE GUIDED SURGERY; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; MEDULLOBLASTOMA; NEURONAVIGATION; NUCLEAR MAGNETIC RESONANCE IMAGING; SCHOOL CHILD; TREATMENT OUTCOME; ADOLESCENT; BRAIN NEOPLASMS; COMPUTER ASSISTED SURGERY; DIAGNOSTIC USE; NEUROSURGERY; PROCEDURES;

ADOLESCENT; AMINOLEVULINIC ACID; BRAIN NEOPLASMS; CHILD; FEMALE; FLUORESCENCE; GLIOBLASTOMA; HUMANS; MALE; MEDULLOBLASTOMA; NEUROSURGICAL PROCEDURES; PHOTOSENSITIZING AGENTS; SURGERY, COMPUTER-ASSISTED;

EID: 84911010102     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2014.913779     Document Type: Article

References (28)

1. Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 2012;117:1032-8.
2. Kuhnt D, Becker A, Ganslandt O, et al. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol 2011;13:1339-48.
3. Orringer D, Lau D, Khatri S, et al. E xtent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg 2012;117:851-9.
4. Stummer W, Reulen HJ, Meinel T, et al.; ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008;62:564-76.
5. Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 2011;153:1211-8.
6. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8.
7. Mineo JF, Bordron A, Baroncini M, et al. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir (Wien) 2007;149:245-53.
8. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62: 753-66.
9. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115:3-8.
10. Vuorinen V, Hinkka S, Färkkilä M, Jääskeläinen J. Debulking or biopsy of malignant glioma in elderly people - a randomized study. ActaNeurochir (Wien) 2003;145: 5-10.
11. Ewelt C, Floeth FW, Felsberg J, et al. Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurol Neurosurg 2011;113:541-7.
12. Nabavi A, Thurm H, Zountsas B, et al.; 5-ALA Recurrent Glioma Study Group. Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study. Neurosurgery 2009;65:1070-7.
13. Stummer W, Pichlmeier U, Meinel T, et al., A LA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392-401.
14. Stummer W, Nestler U, Stockhammer F, et al. Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J Neurooncol 2011;103: 361-70.
15. Stummer W, Tonn JC, Mehdorn HM, et al.; ALA-Glioma Study Group. Counterbalancing risks and gains from extended resections in malignant gliomasurgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. J Neurosurg 2011;114:613-23.
16. Coluccia D, Fandino J, Fujioka M, et al. Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien) 2010;152: 1711-9.
17. Kamp MA, Grosser P, Felsberg J, et al. 5-aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective study. Acta Neurochir (Wien) 2012;154:223-8.
18. Kamp MA, Santacroce A, Zella S, et al. Is it a glioblastoma? In dubio pro 5-ALA! Acta Neurochir (Wien) 2012;154: 1269-73.
19. Porensky P, Chiocca EA. Use of 5-aminolevulinic acid for visualization of low-grade gliomas. J Neurosurg 2011;115:737-9.
20. Preuß M, Renner C, Krupp W, et al. The use of 5-aminolevulinic acid fluorescence guidance in resection of pediatric brain tumors. Childs Nerv Syst 2013;29: 1263-7.
21. Ruge JR, Liu J. Use of 5-aminolevulinic acid for visualization and resection of a benign pediatric brain tumor. J Neurosurg Pediatr 2009;4:484-6.
22. Stummer W, Stocker S, Wagner S, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998;42: 518-26.
23. Floeth FW, Sabel M, Ewelt C, et al. Comparison of (18)F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol Imaging 2011;38:731-41.
24. Hefti M, von Campe G, Moschopulos M, et al. 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: a one-year experience at a single institutuion. Swiss Med Wkly 2008;138:180-5.
25. Ishihara R, Katayama Y, Watanabe T, et al. Quantitative spectroscopic analysis of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence intensity in diffusely infiltrating astrocytomas. Neurol Med Chir (Tokyo) 2007;47:53-7.
26. Heyerdahl H, Wang I, Liu DL, et al. Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues. Cancer Lett 1997;112:225-31.
27. Roberts DW, Valdés PA, Harris BT, et al. Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid). Neurosurg Clin N Am 2012;23:371-7.
28. Shen SC, Lee WR, Fang YP, Hu CH, Fang JY. In vitro percutaneous absorption and in vivo protoporphyrin IX accumulation in skin and tumors after topical 5-aminolevulinic acid application with enhancement using an erbium: YAG laser. J Pharm Sci 2006;95:929-38.